{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:45:35Z","timestamp":1791215135239,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,24]],"date-time":"2015-04-24T00:00:00Z","timestamp":1429833600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13023-015-0265-2","type":"journal-article","created":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T18:06:01Z","timestamp":1429725961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)"],"prefix":"10.1186","volume":"10","author":[{"given":"Arian","family":"Pano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann J","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Bielefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David AH","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,24]]},"reference":[{"key":"265_CR1","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1073\/pnas.70.7.2134","volume":"70","author":"G Bach","year":"1973","unstructured":"Bach G, Eisenberg Jr F, Cantz M, Neufeld EF. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc Natl Acad Sci USA. 1973;70:2134\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"265_CR2","first-page":"3421","volume-title":"The metabolic and molecular bases of inherited disease, Volume III","author":"EF Neufeld","year":"2001","unstructured":"Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease, Volume III. 8th ed. New York: McGraw-Hill; 2001. p. 3421\u201352.","edition":"8"},{"key":"265_CR3","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1542\/peds.2007-1350","volume":"121","author":"R Martin","year":"2008","unstructured":"Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Munoz V, et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008;121:e377\u201386.","journal-title":"Pediatrics"},{"key":"265_CR4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","volume":"32","author":"SA Jones","year":"2009","unstructured":"Jones SA, Almassy Z, Beck M, Burt K, Clarke JT, Giugliani R, et al. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2009;32:534\u201343.","journal-title":"J Inherit Metab Dis"},{"key":"265_CR5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","volume":"10","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J. Initial report from the Hunter Outcome Survey. Genet Med. 2008;10:508\u201316.","journal-title":"Genet Med"},{"key":"265_CR6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","volume":"25","author":"ID Young","year":"1983","unstructured":"Young ID, Harper PS. The natural history of the severe form of Hunter\u2019s syndrome: a study based on 52 cases. Dev Med Child Neurol. 1983;25:481\u20139.","journal-title":"Dev Med Child Neurol"},{"issue":"Suppl 1","key":"265_CR7","first-page":"26","volume":"10","author":"T Ohashi","year":"2012","unstructured":"Ohashi T. Enzyme replacement therapy for lysosomal storage diseases. Pediatr Endocrinol Rev. 2012;10 Suppl 1:26\u201334.","journal-title":"Pediatr Endocrinol Rev"},{"key":"265_CR8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","volume":"13","author":"SG Banugaria","year":"2011","unstructured":"Banugaria SG, Prater SN, Ng YK, Kobori JA, Finkel RS, Ladda RL, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011;13:729\u201336.","journal-title":"Genet Med"},{"key":"265_CR9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99:26\u201333.","journal-title":"Mol Genet Metab"},{"key":"265_CR10","doi-asserted-by":"crossref","unstructured":"Schweighardt B, Tompkins T, Lau K, Jesaitis L, Qi Y, Musson DG, et al. Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome: results from MOR-004, A phase III trial. Clin Ther. 2014. doi: 10.1016\/j.clinthera.2014.11.005.","DOI":"10.1016\/j.clinthera.2014.11.005"},{"key":"265_CR11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","volume":"110","author":"AJ Barbier","year":"2013","unstructured":"Barbier AJ, Bielefeld B, Whiteman DA, Natarajan M, Pano A, Amato DA. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. Mol Genet Metab. 2013;110:303\u201310.","journal-title":"Mol Genet Metab"},{"key":"265_CR12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2014.10.012","volume":"114","author":"EJ Langereis","year":"2015","unstructured":"Langereis EJ, van Vlies N, Church HJ, Geskus RB, Hollak CE, Jones SA, et al. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy. Mol Genet Metab. 2015;114:129\u201337.","journal-title":"Mol Genet Metab"},{"key":"265_CR13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","volume":"103","author":"BK Burton","year":"2011","unstructured":"Burton BK, Whiteman DA. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2011;103:113\u201320.","journal-title":"Mol Genet Metab"},{"key":"265_CR14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/gim.2013.162","volume":"16","author":"R Giugliani","year":"2014","unstructured":"Giugliani R, Hwu WL, Tylki-Szymanska A, Whiteman DA, Pano A. A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. Genet Med. 2014;16:435\u201341.","journal-title":"Genet Med"},{"key":"265_CR15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","volume":"13","author":"J Muenzer","year":"2011","unstructured":"Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13:95\u2013101.","journal-title":"Genet Med"},{"key":"265_CR16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","volume":"8","author":"J Muenzer","year":"2006","unstructured":"Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8:465\u201373.","journal-title":"Genet Med"},{"key":"265_CR17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jim.2011.07.020","volume":"373","author":"M Sellos-Moura","year":"2011","unstructured":"Sellos-Moura M, Barzegar S, Pan L, Shi P, Oommen S, Durant J, et al. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease. J Immunol Methods. 2011;373:45\u201353.","journal-title":"J Immunol Methods"},{"key":"265_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2006.12.004","volume":"321","author":"S Gupta","year":"2007","unstructured":"Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods. 2007;321:1\u201318.","journal-title":"J Immunol Methods"},{"key":"265_CR19","volume-title":"Immunobiology: the immune system in health and disease","author":"CA Janeway","year":"2004","unstructured":"Janeway CA, Travers P, Walport M, Shlomchik M. Immunobiology: the immune system in health and disease. 6th ed. New York: Garland; 2004.","edition":"6"},{"key":"265_CR20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF00973157","volume":"13","author":"M Dittrich","year":"1983","unstructured":"Dittrich M, Milde S, Dinkel E, Baumann W, Weitzel D. Sonographic biometry of liver and spleen size in childhood. Pediatr Radiol. 1983;13:206\u201311.","journal-title":"Pediatr Radiol"},{"key":"265_CR21","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","volume":"1","author":"JR Anderson","year":"1983","unstructured":"Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710\u20139.","journal-title":"J Clin Oncol"},{"key":"265_CR22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"265_CR23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","volume":"13","author":"RJ Desnick","year":"2012","unstructured":"Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet. 2012;13:307\u201335.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"265_CR24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","volume":"14","author":"YH Messinger","year":"2012","unstructured":"Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. 2012;14:135\u201342.","journal-title":"Genet Med"},{"key":"265_CR25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","volume":"96","author":"B Benichou","year":"2009","unstructured":"Benichou B, Goyal S, Sung C, Norfleet AM, O\u2019Brien F. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab. 2009;96:4\u201312.","journal-title":"Mol Genet Metab"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0265-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-015-0265-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0265-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T20:14:15Z","timestamp":1566591255000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ojrd.com\/content\/10\/1\/50"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,24]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["265"],"URL":"https:\/\/doi.org\/10.1186\/s13023-015-0265-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,24]]},"article-number":"50"}}